397 articles tagged with "health"
Trump has instructed federal agencies to expedite the availability of psychedelic treatments and reassess their classification as controlled substances, sparking debate.
The podcast 'Why Should I Trust You?' aims to foster dialogue between MAHA and public health, addressing the critical need for communication between these sectors.
While there is a sense of hope regarding Trump's CDC selection, staff members express caution, particularly regarding RFK Jr.'s influence.
Researchers are exploring innovative molecular techniques to enable cells to deliver treatments directly, potentially revolutionizing healthcare.
This editorial examines the Kemp-Kasten amendment, which restricts U.S. funding to organizations that support abortion-related services, impacting the UNFPA.
Paul Oberstein from NYU Langone's Perlmutter Cancer Center discusses the promising implications of Revolution Medicines' recent study.
A recent analysis sheds light on employer-sponsored health insurance trends affecting 165.6 million individuals under 65, revealing key insights into coverage dynamics.
The FDA is reportedly looking into the possibility of expanding testosterone therapy options, particularly for addressing libido issues, as new research emerges.
Recent research sheds light on the potential dangers associated with ICE detention, alongside discussions on GLP-1s and vaccine skepticism in health news.
The pharmaceutical sector continues to experience notable changes with new hires, departures, and promotions. Here’s a look at the latest personnel shifts within the industry.
Recent findings on Lilly's weight loss pill trials and advancements in U.K. clinical trials highlight evolving perspectives on obesity treatment.
A recent small study suggests that pre-transplant cell therapy may enable some liver transplant patients to discontinue the use of immunosuppressive drugs, indicating a potential shift in treatment approaches.
Recent headlines may suggest a growing skepticism towards vaccines among Americans, but a new poll indicates that this perception may not reflect reality.
As cyberattacks on health care systems escalate, the potential for patient harm grows. Andrea Downing highlights the urgent need for improved defenses against these threats.
A recent ruling provides important insights into navigating issues related to the No Surprises Act, particularly regarding arbitration decisions.
Former public health leader Erica Schwartz has been appointed by Trump to head the CDC, a choice that may resonate well with lawmakers due to her extensive government experience.
A recent report highlights the ongoing struggles many Americans face in affording health care, particularly among uninsured and lower-income populations.
Recent updates on MAHA highlight a significant breakthrough in Duchenne muscular dystrophy, alongside ongoing challenges in cancer treatment and other health developments.
A mother's determination has reignited interest in a neglected class of drugs, potentially benefiting her son and many others with neuromuscular disorders.
A federal judge Tuesday refused to block filling prescriptions for the abortion pill mifepristone by mail across the U.S. — at least for now.
Strategic angle: A new KFF tracker highlights key federal policy actions during President Trump’s second term that concern issues related to mental health and substance use.
Strategic angle: This tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.
Strategic angle: Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout.
Strategic angle: This policy watch examines the United States’ measles elimination status and the potential threats to it.
Strategic angle: In this edition of STAT Health Tech: UnitedHealth Group's big bet on AI to transform its operations, venture funding trends, and more.
Strategic angle: New ideas to bring drug manufacturing to the U.S. are included in Trump's 2027 budget proposal.
Strategic angle: Even as therapies improve, a startling number of cancer patients are not getting genomic tests that could improve their chance of survival.
In a move to enhance local drug production, the FDA has proposed new policies as part of the president's budget, aiming to support domestic drug development.
The stocks of major Medicare Advantage insurers surged on the announcement.
A recent study suggests that limiting insulin prices to $35 per month could enhance adherence to treatment among individuals with type 2 diabetes, highlighting the potential impact of cost on health outcomes.
In a significant move to enhance its oncology pipeline, Gilead has announced the acquisition of Tubulis, a German biotech firm, for more than $3 billion.
With estimates suggesting Merck's experimental HIV prevention pill could cost under $5 annually, researchers are calling for the company to allow generic production.
Strategic angle: A study published in Health Affairs reveals the financial impact of double bonuses on Medicare Advantage spending in Puerto Rico.
Strategic angle: Health Affairs discusses critical issues in healthcare.
Strategic angle: Health Affairs reports positive outcomes from the first year of the ACO program focused on equity and community health.
Strategic angle: A comprehensive study examining the impact of the COVID-19 pandemic on death rates from other causes in the United States.
Strategic angle: Exploring the implications and potential benefits of implementing a Most Favored Nation drug pricing model.
Strategic angle: An analysis of evolving patient cost-sharing practices and their impact on hospital finances.
Strategic angle: A study published in Health Affairs reveals significant reductions in hospital utilization in Maryland compared to other states.
Strategic angle: Analysis of spending trends in mental health and substance use disorder treatment over two decades.
Strategic angle: Brian Donovan had persuaded high school teachers and education researchers that prejudice might be ended by changing how genetics is taught.
Strategic angle: From tariffs to incentives, the administration wants to push companies to manufacture drugs in the U.S.
Strategic angle: People who have been stable for years are suddenly re-exposed to risk — not because their disease worsened, but because their coverage did.
Strategic angle: “Health care will become autonomous because the survival of health systems depends upon it,” writes former Geisinger CEO Glenn Steele.
Strategic angle: For researcher Maiken Nedergaard, ‘diseases of aging are basically all about dirty brains’
Strategic angle: The researchers identified a driving force behind the condition, opening up a potential target for new therapies.
Strategic angle: A bill is moving through the Colorado legislature that would exempt orphan drugs from pricing caps that might be pursued by the state.
Strategic angle: This budget summary provides an analysis of global health funding amounts provided in the President's FY 2027 budget request.
Strategic angle: Examining the state's plans to implement work requirements in Medicaid while facing significant budget challenges.
Strategic angle: Today's announcement will set the tone for how the Trump administration wants to work with private Medicare insurers.
A small biotech company faced a critical setback due to a delayed agreement with the FDA, leading to its closure.
Strategic angle: How thin science fuels peptide hype, blowback to proposed NIH cuts, and more biotech news from The Readout
Strategic angle: A hep B trial raises ethical questions, the peptide hype, and more Morning Rounds news
Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.
Strategic angle: Lifelong disorders require lifelong treatments.
Strategic angle: “There is no off switch when the crisis is your child,” writes Liz Koch.
Strategic angle: UnitedHealth Group is rapidly deploying artificial intelligence tools across its operations. What does it mean for patients?
Strategic angle: Why do RFK Jr. and other health influencers embrace unproven peptides while calling for more research into well-studied vaccines?
Strategic angle: Research indicates that deforestation in tropical regions significantly raises temperatures, contributing to thousands of heat-related fatalities annually.
Strategic angle: Recent research highlights the potential of intestinal bacteria in enhancing physical performance.
Strategic angle: Concerns rise as datacentres compete with residential developments near public transport.
Strategic angle: Congress is expected to resist the proposed reduction in funding for the National Institutes of Health.
Strategic angle: The proposal comes as Congress previously ignored similar cuts, opting instead to increase health spending.
The agency's recent announcement highlights growing public concern over health risks associated with these chemicals.
Strategic angle: From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Strategic angle: Smaller biotechs negotiate with the White House while addressing the trust gap in medicine.
The taxes are part of the president's push to rein in the pharmaceutical industry and bring manufacturing to the U.S.
Strategic angle: Implications of SCOTUS' conversion therapy ruling, Trump hikes drug tariffs, and more Morning Rounds updates
Strategic angle: “The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel.
Strategic angle: Lenacapavir could put the end of the HIV epidemic in reach — if the people who need it can access it. Here’s one way to make that happen.
Strategic angle: A Supreme Court ruling this week on gender and sexuality 'conversion therapy' could narrow the authority of state medical boards over care involving speech.
The Supreme Court's decision challenges state laws against a discredited practice aimed at LGBTQ+ youth.
Strategic angle: A new study reveals that BMI may misclassify a significant number of individuals when assessing health.
Strategic angle: Research from the University of Otago indicates that sexually transmitted infections were less common during the gold rush era than previously believed.
Strategic angle: Scientists have discovered a way to make French fries less greasy without ruining their taste.
Strategic angle: CMS is scaling back the number of measures it uses to grade health insurers.
Strategic angle: The Trump administration is in talks with smaller pharmaceutical companies to establish new drug-pricing agreements.
Strategic angle: How has the FDA's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine?
Strategic angle: An analysis of AI-powered devices that received the FDA's 'breakthrough' label.
Strategic angle: Cuts to health care spending might play a role in a complicated Congressional maneuver to fund immigration enforcement.
Strategic angle: Potential import tariffs on drugs, Foundayo is here-o, and other biotech news from The Readout
Strategic angle: The FDA approves a new obesity pill from Lilly amidst tariff discussions.
Strategic angle: Ahead of the 2026 midterm elections, this KFF issue brief examines the role health care has played in previous elections and its potential impact in 2026.
Strategic angle: A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment.
Strategic angle: When medical misinformation wins, testing an antidepressant for meth use, and other health news.
Strategic angle: How 'Takeover Tuesday' saved biotech's first quarter.
Strategic angle: An analysis of AI-powered devices that received FDA's 'breakthrough' label shows a preference for big-picture, multi-problem solutions.
Strategic angle: Desperate patients, unable to get timely doctors’ appointments, seek help wherever they can find it.
Strategic angle: Prevention is normally relegated to the periphery of national medical conferences. Not anymore.
Strategic angle: A STAT reporter challenges radiologists in identifying deepfake X-rays in this week's STATus Report.
Strategic angle: The White House is readying a 100% tax on some imported medicines, a draft order shows.
Strategic angle: A new study highlights health risks from crops absorbing harmful contaminants and calls for further research.
Strategic angle: Researchers at Aarhus University have developed a microscopic DNA needle that can deliver molecules directly into cells, ensuring their activity.
Strategic angle: The FDA commissioner praised staff and listed his accomplishments in a speech to workers.
Strategic angle: A breakthrough in targeting cancer cells without harming healthy tissue using synthetic DNA strands.
Strategic angle: A new study reveals that AI scribes saved doctors approximately 16 minutes during an eight-hour shift across five academic medical centers.
Strategic angle: A new review reveals the FDA's shortcomings in disclosing financial conflicts of interest among advisory committee members.
The rapper "started feeling very ill" mid-way through the show in New York, her representative told US media.
Eli Lilly’s obesity pill was approved by the FDA, setting it up for fierce competition against Novo Nordisk’s new Wegovy pill.
Strategic angle: This policy tracker documents exceptions in each state’s most restrictive gestational limit or total ban.
Strategic angle: Insights from Alex Zhavoronkov on becoming a productive biotech AI company.
Strategic angle: A delayed FDA decision for Orca Bio, new questions about pharma-telehealth tie-ups, and more
Strategic angle: The FDA is reconsidering its stance on compounding pharmacies, potentially allowing the production of injectable peptides previously banned due to safety concerns.
Strategic angle: A majority of the public expresses concern over immigration enforcement in hospitals amid policy changes.
Strategic angle: A new study explores whether incorporating psychotherapy with ketamine treatment enhances its effectiveness.
Strategic angle: Jay Bhattacharya's claim linking Trump administration policies to Vannevar Bush's vision has ignited controversy.
Strategic angle: “Rigorously derived evidence for the medical efficacy of marijuana is thin,” writes Kevin Sabet.
Strategic angle: Medicare is restricting care for 1 million Americans based on a faulty assumption.
Strategic angle: Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter.
Strategic angle: A quiet effort to change the name of PCOS is nearing completion, driven in part by growing evidence of a male version.
Strategic angle: Taking 60 seconds to listen to a simple tone could make your next trip more enjoyable.
Strategic angle: A new lobbying group tied to the health savings account industry is pushing hard to make HSAs far more widely available.
Strategic angle: A breakthrough in the fight against superbugs and antimicrobial resistance.
Strategic angle: The Trump administration reverts the name of the federal health IT office to the Office of the National Coordinator.
Strategic angle: This guide provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts.
Strategic angle: This chart collection examines how life expectancy in the U.S. compares to that of other similarly large and wealthy countries.
Strategic angle: The scientists who treated Baby KJ say the FDA's strict standards will make it much harder to create bespoke gene editing for others.
Strategic angle: OpenEvidence partners with a significant health system to enhance health record sharing.
Strategic angle: Drugmakers are postponing the release of new medicines in Europe due to shifting pricing policies and pressures from the U.S.
Strategic angle: Lead exposure and heart disease, promoting psychedelics on YouTube, and other health news from Morning Rounds
Strategic angle: Biogen and Eli Lilly make takeover moves, while Doctors Without Borders criticizes Gilead amidst growing concerns in the biotech sector.
Strategic angle: Whoop raised $575 million from investors including the Mayo Clinic and the sovereign wealth fund of Qatar.
Strategic angle: An in-depth look at the public's attitudes toward prescription drugs and their prices based on recent KFF poll findings.
Strategic angle: Biogen is buying Apellis Pharmaceuticals for $5.6 billion upfront as it looks to expand its immunology business.
Strategic angle: U.S. venture capital firms are proactively investing in Chinese biotech, shifting their strategy as competition intensifies.
Strategic angle: “The CDC stands at an inflection point,” write Charles J. Lockwood, Robert C. Gallo, and Sten H. Vermund.
Strategic angle: Deep sleep activates a brain-driven system that enhances growth hormone, impacting muscle strength, metabolism, and mental performance.
Strategic angle: Takeda Pharmaceuticals, the largest biopharma employer in Mass., will lay off 250 workers in Cambridge beginning in July.
Strategic angle: The organization criticized Gilead Sciences after months of negotiations for a limited supply of lenacapavir.
Strategic angle: Shebani Sethi is at the vanguard of metabolic psychiatry, a field that investigates the link between diet and serious mental health disorders.
Strategic angle: Detailed state and national data related to the 2025 Reconciliation Law Medicaid Work Requirements
Strategic angle: Using AI to analyze changes in brain scans can predict Alzheimer’s with nearly 93 percent accuracy, scientists say.
Strategic angle: A JAMA study details how lead lingers in the body and how it can elevate blood pressure, harm blood vessel lining, and raise risk of heart attack.
Strategic angle: The American workforce has grown in large part thanks to the health care industry, but one key sector is cutting back.
Strategic angle: The drug demonstrates improved skin clearance, marking a significant advancement in lupus treatment.
Strategic angle: The next CDC director role, health care giants trimming jobs, and more news from Morning Rounds
Strategic angle: The White House shares legislative text on drug pricing with major pharmaceutical companies.
Strategic angle: Whoever takes over the CDC next will face immediate and enormous challenges. Here are a few.
Strategic angle: Major health insurers are trimming jobs, and Medicaid cuts could soon force hospitals to lay off workers.
Strategic angle: Marc Lipsitch and Yonatan Grad pay tribute to their former colleague and mentor Barry R. Bloom.
Strategic angle: Like it or not, PBMs are fiduciaries.
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.
Strategic angle: A study examining the impact of Alzheimer's disease on mortality rates in taxi and ambulance drivers.
Strategic angle: New research reveals potential dangers of erythritol, a common sugar substitute.
Strategic angle: This tracker presents the most recent Medicaid data on renewals and disenrollments available for each state as well as monthly enrollment data during the unwinding period.
Strategic angle: Infant formula safety, updating labels, defining ultraprocessed foods, and expanding inspections of processing plants are among the priorities.
Strategic angle: This tracker provides U.S. global health funding data by program area and country.
Strategic angle: The White House is working to build support for drug pricing legislation, part of an election year focus on affordability.
Strategic angle: How China's biotech boom is transforming the landscape of global science collaboration amidst an NIH crackdown.
A significant number of NIH-funded scientists report adverse effects from new restrictions on foreign research partnerships.
Strategic angle: From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Strategic angle: Pharmalittle highlights Novo Nordisk's strategic move to enhance consumer engagement by appointing a new board observer.
Strategic angle: This analysis examines the competitiveness of markets for hospital care and finds that nearly half of metropolitan areas across the country had only one or two hospitals or health systems providing general inpatient hospital care in 2024.
Strategic angle: A new study establishes a connection between Agent Orange and MDS blood cancers, potentially aiding veterans in receiving assistance.
Strategic angle: The leading medical school accreditation body in the U.S. has removed language from its standards requiring schools to teach about health inequities.
Strategic angle: Credible nutrition educators and scientists need to be closely involved as medical schools add more instruction on nutrition.
Strategic angle: This intervention improves patient safety, clinician well-being, and hospital finances simultaneously — a rare alignment of incentives in health care.
Strategic angle: Officials allege widespread fraud in home-based care, but evidence remains unprovided.
Strategic angle: Kresladi has shown positive results in a small trial of nine patients.
Strategic angle: Heart to the left. Liver to the right. This normal or abnormal asymmetry can be traced back to tiny structures within the body.
Strategic angle: PathogenFinder2, developed by researchers at DTU, aims to identify genetic traits in unfamiliar bacteria that could lead to disease outbreaks.
Strategic angle: Panel aims to lower costs and enhance care quality with expert advice.
Strategic angle: This analysis highlights the health care affordability challenges facing LGBT adults, a growing population that faces health related disparities.
A preliminary readout from a study could vindicate Allogene Therapeutics' stubborn belief in its off-the-shelf CAR-T treatment.
Strategic angle: In today's Readout Newsletter, Denali and Corcept win FDA approvals, Sarepta eyes a rebound, and Allogene progresses with an off-the-shelf CAR-T.
Strategic angle: In this week's STATus Report, influential health communicators discuss the mental health impacts of social media.
Strategic angle: GOP moves to resolve the fight over ICE's funding could prompt more changes to health care
Strategic angle: In today's Morning Rounds newsletter: White House misses the deadline to nominate a new CDC director, California furthers its crackdown on ultra-processed foods, and more.
Strategic angle: More people use chatbots for health advice, a health AI startup raises $125 million, and all about deepfaked medical images.
A significant decision by the FDA following previous rejections of rare disease treatments.
A recent poll indicates that adults are increasingly relying on AI for health advice, paralleling the use of social media, driven by healthcare costs and access.
Strategic angle: Endometriosis is not just a gynecological disease.
Strategic angle: The recent explosion of perimenopause attention tells women that they are controlled by their hormones.
Strategic angle: Researchers found that immersive dreaming can enhance the quality of sleep, making it feel deeper and more refreshing.
Strategic angle: The search for a new CDC director continues past the statutory deadline, raising concerns about public health leadership.
Strategic angle: A California bill would allow 'not ultraprocessed' labels on foods, even as scientists debate definitions and courts question the legality of similar laws.
Strategic angle: Bhattacharya faced tough staff questions on job cuts and fallout from the shooting attack on the agency.
Strategic angle: A new MRI method measures cardiac oxygen use in three minutes without catheters or radiation, offering a simpler way to study heart failure and metabolism.
Strategic angle: In this edition of STAT's AI Prognosis: A chat with Qualified Health co-founder and CEO, Justin Norden, as the company raises $125 million.
Strategic angle: Sarepta Therapeutics’ next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said.
Strategic angle: An overview of deaths in ICE custody and health care issues during the Trump administration.
Strategic angle: Eli Lilly discusses the 'societal obligation' of GLP-1s amidst other biotech news.
Strategic angle: The acquisition aims to enhance Merck's portfolio with a promising leukemia treatment.
Strategic angle: A federal vaccine adviser departs ACIP, adults turn to AI chatbots for health info, and radiologists sift through deepfake X-rays.
Strategic angle: A new neural implant is so small it can rest on a grain of salt, yet it can track and wirelessly transmit brain activity for over a year.
Strategic angle: Robert Malone, an outspoken doctor and ally of RFK Jr., is stepping away from a panel of federal vaccine advisers after a federal judge blocked the panel’s work.
Strategic angle: Since the Supreme Court’s Dobbs decision, voters in 17 states have weighed in on ballot measures regarding abortion.
Strategic angle: CMS aims to transform fragmented care into a cohesive system for children with complex health needs.
Strategic angle: Settlement expected to save Americans up to $7 billion in out-of-pocket costs over the next decade.
Strategic angle: An analysis reveals that drugmakers penalized for kickbacks paid only a small fraction of their U.S. revenue from the drugs involved.
Strategic angle: Patrick Soon-Shiong, a controversial figure in the biotech industry, was accused by the FDA of making false and misleading claims about a cancer treatment.
Strategic angle: Trump's decisions serve as a test of how much sway RFK Jr.'s MAHA movement still has in the White House.
Strategic angle: An analysis of claims denials and appeals reveals significant challenges for consumers in the ACA Marketplace.
Strategic angle: Deepfake images can mislead viewers, upend elections, and instigate violence. They can also, researchers say, disrupt medical care.
Strategic angle: In this edition of STAT Health Tech: AI doctor startup raises fresh capital, and what Medicare chief Chris Klomp said at STAT Summit.
Strategic angle: This brief describes current coverage of GLP-1s in Medicare and Medicaid, and CMS's efforts to expand access and lower costs through the BALANCE model.
Strategic angle: In today's Readout newsletter: Gilead to acquire an immunology biotech and Merck partners with Flagship company on IBD targets.
Strategic angle: Comments from a top Trump administration health official highlight significant issues in the president’s drug pricing plans.
Strategic angle: Penn Engineers have redesigned a key component of lipid nanoparticles to enhance targeting and reduce off-target effects.
Strategic angle: In this excerpt from their new book “Whiplash,” David Blumenthal and James A. Morone describe how scientists became villains to MAGA.
Strategic angle: Diverging messages on the main effort to address U.S. drug prices point to a loophole in Trump's plan.
Strategic angle: A passion for snakes opened a crack in the religious beliefs science communicator Paul Martin Jensen grew up with in a end-times Pentecostal church.
Strategic angle: Research reveals a link between antimicrobial resistance and agricultural practices.
Strategic angle: A proposal in the Tennessee legislature could force CVS Health to sever a core piece of its business model or exit the state entirely.
Strategic angle: A new study reveals that women, especially early-career researchers, face greater challenges due to NIH grant terminations.
Strategic angle: A STAT investigation explores how a new company is profiting from the arbitration process in the No Surprises Act.
Strategic angle: Our updated explainer provides an overview of comprehensive managed care, the most common way states deliver Medicaid services to enrollees.
Strategic angle: A recent lawsuit by Epic reveals a company allegedly posing as a provider to access patient records, raising concerns over oversight.
The escalating war in the Middle East so far has not appreciably disrupted global pharmaceutical supply chains, but it could eventually — affecting prices.
Strategic angle: New results on Pfizer's Lyme disease vaccine raise questions about its regulatory approval.
Strategic angle: In today's Morning Rounds newsletter: the high-stakes search for a new CDC director, the impact of immigration policy on budding doctors, and more.
Strategic angle: Doctronic, the startup behind a provocative experiment in Utah to renew drug prescriptions with a chatbot, has raised $40 million.
Strategic angle: Insmed hopes to convert Arikayce's accelerated approval to a full approval.
Strategic angle: A new vaccine shows some promise in combating Lyme disease, which affects nearly half a million Americans annually.
Strategic angle: A mother's struggle to secure a life-saving treatment for her son amidst challenges.
Strategic angle: Health care’s adoption of AI should move at the speed of trust, not investment, writes Oni Blackstock.
Strategic angle: This fact sheet provides a snapshot of global malaria efforts and examines the U.S. government’s role in addressing malaria worldwide.
Strategic angle: Isis Sio, 19, is in a medically induced coma following a knockout during a recent bout.
Strategic angle: Opioid-class drugs pose overdose risks for both humans and pets, highlighting the importance of Naloxone training.
Strategic angle: A lactic acid bacterium from kimchi may aid in removing harmful nanoplastics from the body.
Strategic angle: A study of 340,000 adults suggests not all alcohol carries the same risk.
Strategic angle: Aging men often lose the Y chromosome in a growing number of their cells, linked to serious health risks.
Strategic angle: The idea could be a major win for the health insurance industry, which has seen a crackdown on Medicare Advantage in recent years.
Strategic angle: A significant rise in sepsis cases raises questions about the accuracy of hospital billing practices and the role of AI in medical coding.
Strategic angle: Top HHS official Chris Klomp discusses the challenges of finding a new leader for the CDC.
Strategic angle: The Trump administration faces a pivotal decision on vaccine policymaking following a court ruling, with potential political ramifications.
Strategic angle: Today's biotech news includes insights from the Medicare director on the scope of TrumpRx and the FDA's approval of high-dose Wegovy.
Strategic angle: From new hires to departures and promotions, here are the latest comings and goings in the pharmaceutical industry.
Strategic angle: This week on 'The Readout LOUD,' a conversation with biotech 'godfather' Stelios Papadapolous live from #STATBreakthrough.
Strategic angle: In today's Morning Rounds newsletter, the highlights from #STATBreakthrough, a ruling against Kennedy’s gender-affirming care declaration, and more.
Strategic angle: Exploring expectations around TrumpRx and a new high-dose version of Wegovy.
Strategic angle: Following successful appeals from drugmakers, the U.K. is reviewing the cost-effectiveness of two new Alzheimer's treatments.
Strategic angle: The Broad Institute of MIT and Harvard is poised to receive a massive injection of cash to fund research in the understanding and treatment of bipolar disorder and schizophrenia.
Strategic angle: James Gelfand and Patricia Kelmar argue for urgent reforms to the No Surprises Act to protect patients and employers from financial ruin.
Strategic angle: The farm bill shows politicians catering to the agriculture industry risk losing the support of MAHA while running afoul of public health goals.
Strategic angle: A new study reveals that sleep tracking devices may exacerbate anxiety in individuals suffering from insomnia by intensifying their focus on sleep quality.
Strategic angle: A large study reveals that stopping Ozempic may not lead to significant weight regain for most users.
Strategic angle: Pets encounter various risks, including invisible threats from metal-related toxicities that owners may underestimate.
Strategic angle: Robert Califf highlights the shift towards political decision-making in the FDA during the Trump administration.
Strategic angle: A U.S. district judge is set to rule against a declaration by Kennedy regarding the medical standards of gender-affirming care for young trans individuals.
Strategic angle: A new Cornell study highlights the benefits of nature breaks in reducing workplace stress.
Strategic angle: If the U.S. wants to hold on to its title as the world's top biotech innovator, it might want to take a page out of China's book.
Strategic angle: A group of autism scientists kicked off efforts Thursday to influence Congress, and the research agendas of private organizations.
Strategic angle: The Trump administration is counting on its drug pricing efforts to help with the midterm elections.
Strategic angle: A comprehensive timeline of public health policy actions by the Department of Health and Human Services (HHS) under the Trump administration from 2025-2026.
Strategic angle: This page tracks recent state actions to extend Medicaid postpartum coverage.
Strategic angle: Congress has repeatedly extended several pandemic-era flexibilities around Medicare coverage of telehealth, but most remain temporary.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.
Democrats are sharpening their health care message as the midterms loom.
Strategic angle: Eli Lilly's 'triple-G' drug shows potency, In-vivo CAR-T inches toward clinical reality, and more in today's Readout newsletter.
Strategic angle: The Examination explores the impact of coal power expansion on a mining town in India.
Strategic angle: In this edition of STAT Health Tech: How Apple Watch is being used in a clinical trial for a Parkinson's drug, and more
In today's Morning Rounds newsletter, a Texas couple getting rich off out-of-network medical bills, two doctors on the challenges of medicine today, and more.
Strategic angle: UNM's RESEP provides essential support for uranium miners facing radiation exposure.
Strategic angle: New strength training guidelines emphasize that doing any resistance training is what truly matters.
Strategic angle: Diabetes patients taking an investigational drug from Eli Lilly saw significant reductions in their blood sugar and weight in a late-stage study.
Strategic angle: Will the FDA’s regulatory policies, particularly for rare-disease drugs, shift in the wake of Vinay Prasad’s imminent departure?
This KFF survey examines the cost concerns and coverage changes experienced by ACA Marketplace enrollees in 2025 following the expiration of enhanced benefits.
Strategic angle: Nursing homes misuse antipsychotic drugs for dementia patients, disguising the practice as schizophrenia treatment, a watchdog finds.
Strategic angle: Adam Sherwat, the director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, is leaving the agency.
Strategic angle: A breakthrough sensor developed by La Trobe University tracks molecular changes in blood, enabling real-time personalized medicine.
Strategic angle: The Covid-19 pandemic's early death toll was much higher than the official U.S. count, according to a new study that spotlights dramatic disparities in the uncounted deaths.
Strategic angle: A new bill aims to mandate drugmakers and patient groups to reveal their connections to disease awareness initiatives.
Strategic angle: A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut costs and expand access.
Strategic angle: STAT's AI Prognosis takes a closer look at how the U.S. moonshot agency for health research is developing AI agents for deployment in hospitals.
Strategic angle: A Huntington's researcher treads lightly into the UniQure-FDA fray, J&J wins approval for a first-of-its kind psoriasis pill, and more in today's Readout newsletter.
Strategic angle: JAMA Cardiology study highlights the increased heart disease risk associated with premature menopause, particularly among Black women.
Strategic angle: As the Trump administration goes after fraud in health care, advocates say the disability community feels singled out.
Strategic angle: U.S. health officials claim TrumpRx offers Americans the world’s lowest prices on prescription drugs, but a new analysis found that is not true.
Strategic angle: The HHS has made reducing animal testing a priority over the past year.
Strategic angle: Test your knowledge on health insurance with this 10-question quiz to make informed decisions about your coverage.
Strategic angle: A new study suggests a snail-derived compound may reduce the risk of excessive bleeding associated with traditional anticoagulants.
Strategic angle: Johnson & Johnson's new daily psoriasis pill offers benefits comparable to injectable treatments, potentially disrupting a multibillion-dollar market.
Strategic angle: A new study reveals that opioid smokers are four times more likely to suffer severe burns compared to those who inject drugs.
Strategic angle: Hallway beds cut into the bones that sustain emergency medicine, shaving away layers of moral tenets and high standards.
Strategic angle: Leaving her career as a surgeon, Frances Mei Hardin writes, “was the beginning of a life I actually wanted.”
Strategic angle: At Empa, researchers are developing innovative methods to combat harmful bacteria and viruses using advanced nanomaterials.
Strategic angle: Research from the Department of Environmental Health Sciences explores how common sunscreen ingredients behave under light exposure.
Strategic angle: Jay Bhattacharya assures House appropriators that the NIH will utilize its entire budget by the end of the fiscal year 2026.
Strategic angle: This fact sheet identifies key U.S. government global health positions and officials.
Strategic angle: A new Peterson-KFF policy explainer lays out the health care trends shaping the 2026 policy debates.
Strategic angle: A buzzy venture capital firm has started raising its third fund, hoping to amass around $700 million to invest in companies that meld AI and science.
Strategic angle: The meeting of the Advisory Committee on Immunization Practices that was scheduled for this week has been postponed.
Strategic angle: Trump adds pressure to codify MFN, a judge stalls Kennedy's changes to vaccine policy, and more biotech news.
Strategic angle: This issue brief reviews the abortion-related initiatives currently slated to be on the ballot in November 2026 and examines how these measures may impact abortion access in the state.
Strategic angle: The CDC had remarkable data on smoking rates last fall, but it no longer had smoking experts available to review it and disseminate it.
Strategic angle: An update on Epic's lawsuit over alleged improper access to health records, Nvidia's new radiology AI partnership, and more.
Strategic angle: How to type with your mind, who might not need to take blood pressure meds, and other health news.
Strategic angle: The White House intensifies pressure on Congress for drug pricing legislation.
Strategic angle: A group of researchers are launching an effort to validate big scientific claims, with help from artificial intelligence.
Strategic angle: New analysis reveals that NIH is significantly behind on grant spending as the 2026 fiscal year progresses.
Strategic angle: Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.
Strategic angle: After 50 years of operation, FQHCs are discovering that their financial structure has not kept pace with the realities of delivering on their mission.
Strategic angle: A redesigned cancer immunotherapy shows promising early results, potentially changing the landscape of cancer treatment.
Strategic angle: Researchers project that reduced activity could contribute to half a million additional premature deaths annually by 2050.
Strategic angle: In a rebuke, a federal district court judge blocked the administration's reduction in the number of immunizations recommended for kids and also changes to an influential vaccine committee.
Strategic angle: A federal judge on Monday stalled major parts of health secretary Robert F. Kennedy Jr.’s campaign to remake vaccine policy in the U.S.
Strategic angle: One of the most interesting health care legal cases right now, big Medicaid approvals, and more.
Strategic angle: Families report financial and treatment struggles after GSK's price increases on asthma inhalers.
Strategic angle: CMS has announced a new strategy focusing on pausing or withholding federal funding in potential fraud cases, impacting states and enrollees.
Strategic angle: Two people with paralysis were able to type using a brain-computer interface that decodes attempted finger movement, a new study showed.
Strategic angle: Campaigners urge for immediate pollution alerts following a serious health incident involving a young boy.
Strategic angle: Medicare delays stall breakthrough device access, ALS carriers fear research setbacks under Trump, and more biotech news
An experimental obesity pill from Structure Therapeutics helped patients lose significant weight in a mid-stage trial, with a Phase 3 study in the works.
Strategic angle: The transformation of organ transplantation, an age to start considering statins, and other health news
Strategic angle: Arielle Duhaime-Ross shares how technology helps manage chronic health issues.
Strategic angle: Perfusion technology vastly improves organ quality in transplants, but high costs and coverage questions pose barriers in becoming the standard of care.
Strategic angle: Congress must pass bipartisan legislation to ensure Medicare coverage of breakthrough medical technologies, writes a physician and inventor.
Strategic angle: "Watching my mom die of ALS was one of the most awful things I’ve gone through. I don’t want my children to see me suffer like that."
Strategic angle: The Asian financial crisis of the late 1990s had lasting impacts on children's health in Indonesia.
Strategic angle: Recent analysis reveals that many headphones on the Central European market are contaminated with harmful chemicals.
Strategic angle: New research reveals alarming levels of PFAS compounds in fetal blood samples.
Strategic angle: It's Oscar season, so we're bringing you a special STATus report on how we'd cover the drug scandal in 'The Fugitive' if it were real.
Strategic angle: Cardiology groups say adults as young as 30 should assess cholesterol risk and consider treatment to prevent heart attacks and strokes.
Strategic angle: From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Strategic angle: Virtually all (98.9%) of the 2.6 million Medicare beneficiaries enrolled in a Medicare Advantage plan that terminated coverage at the end of 2025 have at least one MA-PD available in 2026.
On this week's The Readout LOUD podcast: A friend of Jeffrey Epstein attempts a biotech comeback, and (another) Prasad FDA exit.
Strategic angle: Exploring the ongoing battle over drug pricing and the contrasting approaches of Trump and Biden.
This issue brief describes recent trends in the number of Medicaid outpatient prescriptions and the spending on those drugs and examines the implications of recent federal actions on future trends.
Strategic angle: Vaccine skepticism, FDA-authorized vape flavors, and more health news from Morning Rounds
Most Across Political Parties Want Government to Do More to Regulate Prices
Strategic angle: Trump is drawing more attention to his efforts to lower drug prices, like TrumpRx.
Strategic angle: New FDA guidance suggests mint, coffee, and spice vape flavors could be authorized, raising debate over toxic additives and youth vaping risks.
Strategic angle: The legal battle underscores the complicated questions surrounding how best to evaluate hospital safety.
Strategic angle: As Trump political advisers try to move on from vaccine policy debates, MAHA movement insiders push back, calling RFK Jr. supporters vital to GOP's success.
Strategic angle: Lobbying groups supported by insurance companies have criticized the research and promoted their own.
Strategic angle: An unexpected discovery may bring scientists closer to a long-sought goal: finding an ideal immunotherapy target for solid tumors.
Strategic angle: A University of Helsinki study reveals the effectiveness of treated wood surfaces against bacterial adhesion and survival.
Strategic angle: Exploring the intricate biological processes that twins reveal through advanced computational systems.
Strategic angle: Exposure to gun violence can severely affect the mental health of children and adolescents.
Strategic angle: This brief analyzes the latest youth mortality data from the CDC, revealing alarming trends in firearm-related deaths among children and adolescents.
Strategic angle: Explore the current status of state decisions on Medicaid expansion under the Affordable Care Act.
Strategic angle: BIO's Crowley warns U.S. risks losing lead, a familiar red flag with Aldeyra, and other biotech news from The Readout.
Strategic angle: A new analysis reveals that mental health specialists utilizing telehealth did not significantly increase their rural patient base.
Strategic angle: Medical groups affiliated with telehealth companies the FDA warned about marketing of compounded weight loss drugs may be under the microscope, too
Strategic angle: The doctors behind the telehealth GLP-1 boom, a men's health office moment, and other health news
Strategic angle: The EPA's safety review of fluoride coincides with growing state-level bans on community water fluoridation.
Strategic angle: How often do drugmakers complain about short sellers in SEC filings? And does it do any good?
Strategic angle: The FDA is scrutinizing telehealth marketing practices for GLP-1 drugs, raising questions about prescribing trends.
Strategic angle: For advocates who have been pushing to create a federal office of men's health, this could finally be the moment.
Strategic angle: The federal government negotiates prices for high-cost drugs under Medicare Part B and Part D.
This approval follows previous claims of its potential use in treating autism symptoms.
It's the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices.
Strategic angle: In this edition of AI Prognosis: Seemay Chou and Becky Pferdehirt's bold vision for how Radial will change science for AI
Strategic angle: This analysis examines how U.S. health spending compares to health spending in other high-income nations.
Strategic angle: Epstein's "great friend" returns to biotech, sex differences in suicide, and other health news from Morning Rounds
Strategic angle: Radial aims to transform the scientific landscape to better integrate artificial intelligence.
Strategic angle: Experts at HIMSS 2026 raise alarms over the lack of validation for AI agents in health care.
Strategic angle: In medical school, a student writes, she has learned to react first, focus on prevention later.
Strategic angle: Boris Nikolic’s career looked to be in tatters after his friendship with Jeffrey Epstein came to light in 2019. But he has quietly made a comeback, with some help from…
Strategic angle: This analysis explores trends in how the cost of healthcare affects access to care in the U.S.
Strategic angle: Sen. Ron Johnson raises concerns about the FDA's handling of treatments for rare diseases after discussions with Commissioner Marty Makary.
Strategic angle: A coalition of Kennedy's allies gathered to discuss vaccines, but the health secretary was rarely mentioned.
Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.
Strategic angle: New research reveals that antibiotic resistance measurements are influenced by environmental conditions.
Strategic angle: AI scribe company Nabla aims to be much more by using tech from Yann LeCun's new startup AMI, which just raised $1 billion.
Strategic angle: The co-founders of BioNTech, known for their Covid-19 vaccine, are set to leave the company to launch a new mRNA-focused venture.
Strategic angle: Epilepsy med response, a long-awaited fix to the kidney transplant system, and more health news
Strategic angle: An overview of oral contraception, insurance coverage, and strategies to enhance access for women.
Strategic angle: The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% over the past five years, according to a new analysis.
Strategic angle: A significant change in the eGFR algorithm led to increased kidney transplant opportunities for Black patients.
Strategic angle: FDA approves Opill, marking a significant change in access to oral contraceptives in the U.S.
Strategic angle: An international team of researchers has modified a probiotic yeast to enhance safety for vulnerable populations.
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
Strategic angle: This tracker provides up-to-date information on countries with signed bilateral MOU global health agreements with the U.S.
Strategic angle: A study reveals how orthohantaviruses, like the Puumala virus, pose a significant zoonotic threat by affecting human cell structure.
Strategic angle: A battle between doctors and a hospital system is an early test of a new law designed to separate business and medicine.
Strategic angle: Tracking the status of Section 1115 Medicaid waivers across states, highlighting approved and pending provisions.
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Strategic angle: Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug.
Strategic angle: Prasad out again, generic Ozempic on its way, and more health news from Morning Rounds
Strategic angle: Growing worries about the FDA's diminishing use of advisory committees for public discourse.
Strategic angle: Universal Health Services announces acquisition of virtual mental health company Talkspace.
Strategic angle: Xenon Pharmaceuticals reported significant reduction in seizure frequency with its new treatment compared to placebo.
Strategic angle: A new data analysis from Blue Cross Blue Shield shows how AI coding may be driving up the cost of health care.
Strategic angle: How a remote patient monitoring company is reworking its tech to enroll in a Medicare program seeking to align payment with health care outcomes.
Strategic angle: Parents often pressure Lawrence Diller, a behavioral/developmental pediatrician, to diagnose their children with autism. He thinks he knows why.
Strategic angle: The FDA is cutting back on public advisory committee meetings, even as the public and other stakeholders seek more transparency.
A study in Health Affairs indicates that the new risk-adjustment model from CMS has not substantially altered Medicare Advantage benefits for the 2024-25 period.
Strategic implications in focus: An overview of critical issues in health care as discussed in Health Affairs.
A recent study highlights that most family physicians remain in the states where they trained, raising questions about workforce distribution and healthcare access.
Strategic implications in focus: Health Affairs, Volume 45, Issue 3, Page 238-245, March 2026.
A comprehensive analysis reveals troubling trends in primary care physician satisfaction in the US and nine comparator nations, indicating systemic issues that could affect healthcare outcomes.
Recent findings suggest that while private equity is driving investment in primary care, clinician growth is tempered by a notable increase in exits.
A recent study indicates that disenrollment rates for Medicare Advantage beneficiaries have tripled between 2017 and 2022, prompting questions about plan stability.
A study spanning 2000 to 2021 reveals concerning mortality trends among SSDI beneficiaries awaiting Medicare, highlighting systemic healthcare risks.
An examination of nursing home staffing mandates from 2010 to 2023 shows increased staffing levels with negligible financial impact and no notable rise in closures.
A recent study highlights the complex dynamics between labor unions and nurse staffing ratios in US nursing homes, with implications for care quality.
Strategic implications in focus: Vinay Prasad's unique ability to attract criticism — even when his bosses, including the president, wanted him to keep his head low — did him in at the FDA.
The cancellation of the first public meeting of the federal autism advisory board, post-reconstitution, highlights potential operational inefficiencies and stakeholder engagement risks.
Strategic implications in focus: Recent FDA decisions could complicate the Trump administration's relationship with drugmaker UniQure.
Strategic implications in focus: A list of the implementation questions relating to the Medicaid work requirements in the 2025 Reconciliation law.
Moderna's pivot to oncology reflects broader trends in biotech, with potential risks and opportunities for investors and stakeholders.
Servier's acquisition of Day One Biopharmaceuticals for $2.5 billion could reshape its position in the pediatric oncology market, but risks remain.
Strategic implications in focus: China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded.
Strategic implications in focus: The DOJ's fight against gender-affirming care, the impact of Trump's 'Don't take Tylenol,' and more health news.
Strategic implications in focus: This collection of charts explores the variation in health spending across the population through an analysis of 2023 Medical Expenditure Panel Survey (MEPS) data.